<div id="readability-page-1"><ul><li>Biohaven Insiders Bet $33 Million on a Turnaround</li></ul><p>Biohaven Ltd. (NYSE:BHVN - Free Report) - Stock analysts at HC Wainwright lifted their FY2025 earnings per share (EPS) estimates for shares of Biohaven in a research note issued on Wednesday, December 3rd. HC Wainwright analyst D. Tsao now expects that the company will post earnings per share of ($6.28) for the year, up from their previous forecast of ($8.73). HC Wainwright currently has a &#34;Neutral&#34; rating and a $11.00 price objective on the stock. The consensus estimate for Biohaven's current full-year earnings is ($8.90) per share. HC Wainwright also issued estimates for Biohaven's Q4 2025 earnings at ($0.53) EPS, FY2026 earnings at ($2.02) EPS, FY2027 earnings at ($1.65) EPS and FY2028 earnings at ($0.16) EPS.</p><p>Biohaven (NYSE:BHVN - Get Free Report) last posted its quarterly earnings data on Monday, November 10th. The company reported ($1.64) earnings per share for the quarter, topping the consensus estimate of ($1.91) by $0.27. </p><ul><li>Biohaven Stock Soars on Drug Trial Results: Time to Jump In?</li></ul><p>BHVN has been the topic of a number of other reports. Raymond James Financial  reiterated a &#34;strong-buy&#34; rating on shares of Biohaven in a report on Wednesday, November 5th. Citigroup decreased their target price on shares of Biohaven from $28.00 to $14.00 and set a &#34;buy&#34; rating for the company in a research report on Thursday, November 13th. Morgan Stanley lowered their price target on shares of Biohaven from $54.00 to $26.00 and set an &#34;overweight&#34; rating on the stock in a research note on Tuesday, November 18th. Leerink Partners reduced their price objective on shares of Biohaven from $60.00 to $50.00 and set an &#34;outperform&#34; rating for the company in a research note on Tuesday, August 12th. Finally, Weiss Ratings  reaffirmed a &#34;sell (d-)&#34; rating on shares of Biohaven in a research report on Monday, December 1st. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, six have issued  a Hold rating and one  has issued  a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $25.93.</p><p><b>Get Our Latest Stock Report on BHVN</b></p><h2>Biohaven Trading Down 0.5%</h2><p>NYSE BHVN opened at $9.56 on Monday. Biohaven has a 52 week low of $7.48 and a 52 week high of $45.87. The company has a debt-to-equity ratio of 1.91, a quick ratio of 2.86 and a current ratio of 2.86. The stock's 50 day moving average price is $12.89 and its two-hundred day moving average price is $14.11. The stock has a market capitalization of $1.01 billion, a price-to-earnings ratio of -1.26 and a beta of 1.14. </p><h2>Insider Activity</h2><p>In other news, Director Gregory Bailey bought 400,000 shares of the business's stock in a transaction that occurred on Thursday, November 13th. The stock was acquired at an average cost of $7.50 per share, for a total transaction of $3,000,000.00. Following the purchase, the director owned 2,020,071 shares of the company's stock, valued at approximately $15,150,532.50. This trade represents a 24.69% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Vlad Coric purchased 666,666 shares of Biohaven stock in a transaction that occurred on Thursday, November 13th. The shares were acquired at an average price of $7.50 per share, with a total value of $4,999,995.00. Following the acquisition, the chief executive officer directly owned 1,195,275 shares of the company's stock, valued at $8,964,562.50. This trade represents a 126.12% increase in their position. The SEC filing for this purchase provides additional information. Insiders purchased a total of 4,416,999 shares of company stock valued at $33,144,833 in the last 90 days. 14.60% of the stock is owned by company insiders. </p><h2>Institutional Investors Weigh In On Biohaven</h2><p>A number of large investors have recently added to or reduced their stakes in BHVN. SVB Wealth LLC acquired a new stake in  Biohaven during the 1st quarter valued at $25,000.  PNC Financial Services Group Inc. raised its position in shares of  Biohaven by 53.7% in the first quarter. PNC Financial Services Group Inc. now owns 1,783 shares of the company's stock valued at $43,000 after purchasing an additional 623 shares during the period.  PFS Partners LLC acquired a new stake in shares of  Biohaven during the 3rd quarter worth about $60,000.  US Bancorp DE lifted its stake in shares of  Biohaven by 62.8% during the 1st quarter. US Bancorp DE now owns 4,837 shares of the company's stock worth $116,000 after buying an additional 1,866 shares during the last quarter.  Finally, Elkhorn Partners Limited Partnership boosted its holdings in shares of  Biohaven by 26.1% during the 2nd quarter. Elkhorn Partners Limited Partnership now owns 5,800 shares of the company's stock worth $82,000 after buying an additional 1,200 shares during the period. Institutional investors own  88.78% of the company's stock. </p><h2>About Biohaven</h2> (Get Free Report)<p>Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Biohaven</li><li>Why is the Ex-Dividend Date Significant to Investors?</li><li>Rubrik’s Massive Rebound: Why the Next Leg Higher Could Be Fast</li><li>What Are the U.K. Market Holidays? How to Invest and Trade</li><li>Five Below and Dollar Tree Earnings Signal a Shopper Shift</li><li>Stock Analyst Ratings and Canadian Analyst Ratings</li><li>Ulta’s Stock May Be Set for a Glow-Up—20% Upside Ahead?</li></ul> <p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJIVk4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJIVk4"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Biohaven Right Now?</h2><p>Before you consider Biohaven, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biohaven wasn't on the list.</p><p>While Biohaven currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

BHVN

<p>HC Wainwright increased Biohaven's FY2025 EPS estimates from ($8.73) to ($6.28), maintaining a "Neutral" rating with a $11.00 price target. Biohaven's stock has mixed ratings, with a consensus "Moderate Buy" and an average target price of $25.93. Insiders have invested $33 million in shares, indicating confidence in a turnaround. The stock trades at $9.56, with a market cap of $1.01 billion.</p>

FY2025 EPS Estimates for Biohaven Increased by HC Wainwright